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Abstract 
Objective: To compare the efficacy and 
tolerability of celecoxib to hyoscine butyl bromide 
(HBB) and placebo in reducing pain scores during 
placement of copper intrauterine devices (IUD) in 
parous women who have undergone elective 
cesarean section and who have had no previous 
vaginal deliveries.  
Methods: We conducted a randomized, double-
blind, placebo-controlled trial at a tertiary 
University hospital from April 2018 to September 
2018. The study included women who had never 
delivered vaginally and who desired copper IUD 
insertion. We randomized the study participants 
in a 1:1:1 ratio to celecoxib, HBB or placebo 
groups. They took the tablets orally two hours 
before IUD insertion. The study outcomes were 
the self-reported pain measurements, using a 10-
cm Visual Analogue Scale (VAS), taken during 
tenaculum placement, sound insertion, IUD 
insertion and five minutes post-insertion, as well 
as an ease of insertion score.  
Results: The study included 105 women (n=35 in 
each group). The baseline characteristics were 
similar among all groups. The mean pain score in 
the celecoxib group was lower during IUD 
insertion than placebo (1.97 vs 4.34, p<0.001). 
Moreover, the ease of insertion score was 
significantly better with celecoxib [1.56 vs. 3.03, 
p< 0.001] than with placebo. Similarly, Women in 
the HBB group were more likely to report lower 
pain scores during IUD insertion (2.91 vs 4.34, 
p<0.001) and lower ease of insertion score [1.43 
vs. 3.03, p< 0.001]. 
Conclusions: The use of celecoxib and HBB 
may both reduce the pain associated with copper 
IUD insertion among women with no previous 
vaginal delivery. However, celecoxib is better 
tolerated with fewer side effects. 
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Introduction 
The intrauterine device (IUD) is 
considered one of the most effective 
long-acting, reversible contraception 
(LARC) methods with a lower incidence 
of failure when compared with other 
reversible contraception methods. 
Despite its effectiveness, it is still an 
underutilized method of contraception in 
many countries.1,2 This might be 
attributed to the pain associated with the 
insertion procedure.3 
Several medications have been used to 
decrease pain during the procedure 
including the use of topical anesthesia, 
opioids, misoprostol, paracervical block 
and non-steroidal anti-inflammatory 
drugs (NSAIDs).4-11 Various NSAIDs 
have been shown to decrease pain 
associated with copper IUD insertion, 
including studies on diclofenac, 
naproxen, indomethacin, ibuprofen, and 
ketorolac.5,12-15  All these agents are non-
selective cyclooxygenase-1 (COX-1) and 
COX-2 inhibitors with common 
gastrointestinal adverse effects. 
Celecoxib is a relatively new selective 
COX-2 inhibitor. COX-1 has a role in the 
protection of the gastrointestinal mucosa, 
hemodynamics of the kidney, and 
platelet thrombogenesis, whereas COX-
2 produces prostaglandins, which are 
triggered by inflammation and cause 
pain. Therefore, the use of COX-2 
inhibitors leads to pain reduction with 
fewer of the gastrointestinal adverse 
effects that are relatively common with 
non-selective NSAIDs.16 
Hyoscine butyl-bromide (HBB) is an 
antispasmodic drug used for relief of 
muscle spasms. Its main action on the 
pelviabdominal parasympathetic ganglia 
is through blocking the transmission of 
neural impulses and inhibiting cholinergic 
transmission in the synapses, thus 
relieving spasm in the smooth muscles of 
gastrointestinal, biliary, urinary and 
genital organs.17 Moreover, previous 
studies have proven its effect on 
shortening the duration of labor due to its 
cervical spasmolytic action.18,19 
Therefore, the current study aims to 
compare the effectiveness and side 
effects of oral celecoxib and HBB to 
placebo in decreasing pain associated 
with copper IUD placement among 
multiparous women delivered only by 
elective cesarean section. 
Materials and Methods 
Study type, setting, and duration 
A randomized, double-blind, placebo-
controlled (RTC) study was carried out at 
the Kasr Al-Ainy Family Planning Clinic, 
Cairo, Egypt between April 2018 and 
September 2018. This study was 
designed and reported according to the 
revised recommendations of 
ClinicalTrials.Gov for improving the 
quality of reporting RCTs (registered trial; 
NCT03499743). The institutional review 
board approved the study, and we 
obtained written informed consent from 
all participants before enrollment in the 
study. 
Study participants 
We invited all women who attended the 
Family Planning Clinic requesting an IUD 
placement during the study period to 
participate in the study. We included 
women with the following inclusion 
criteria: multiparous, delivered by 
elective cesarean section (CS), aged 18-
49 years, and who did not take any 
analgesics, sedatives or misoprostol in 
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the 24 hours before insertion. We 
excluded women who were not eligible 
for IUD placement according to World 
Health Organization (WHO) eligibility 
criteria.20 Additionally, we excluded 
women with suspected pregnancy, 
history of dysmenorrhea, those who 
presented for IUD removal and 
reinsertion, women with a neurological 
illness that results in altered pain 
sensation and, finally, those with allergy 
or contraindication to HBB. 
Sample size  
Validity considerations for this study were 
based on work by Abbas, et. al.21 in their 
study of diclofenac (assumed to be 
similar to celecoxib) for pain relief during 
IUD insertion in hopes of matching or 
beating their VAS values for mean±SD of 
3.66± 0.87. We hypothesized that HBB 
would be at least as effective as 
celecoxib in pain reduction. Pain ratings 
with a difference of 2 cm along the 10 cm 
VAS used for this study determined to 
show a clinically significant difference 
between study groups.8 
Accordingly, the minimum sample size 
was 35 participants in each arm to be 
able to reject the null hypothesis with 
80% power at α = 0.05 level using a one-
way analysis of variance test. Sample 
size validity calculation was done using 
G*Power software version 3.1.2 for MS 
Windows, Franz Faul, Kiel University, 
Germany. 
Allocation 
Eligible participants were randomly 
divided into three equal groups. We used 
a double dummy technique to ensure 
blinding. Group (I) women received 
celecoxib 200 mg (Celebrex® 200 mg, 
Pfizer, USA) plus a placebo tablet similar 
in shape and size to HBB. Group (II) 
women received HBB 10 mg (Buscopan® 
10 mg, Sanofi-Aventis Ireland Ltd. 
Dublin, Ireland) plus a placebo tablet 
similar in shape and size to celecoxib. 
Group (III) women received two placebo 
tablets, one each of similar color, shape 
and size for both HBB and celecoxib. 
Placebo tablets were manufactured in 
the Department of Pharmaceuticals, 
Faculty of Pharmacy, Cairo University. 
All tablets were taken under the 
supervision of one of the study 
investigators orally two hours before IUD 
insertion. The pharmacy dispensed the 
study medications based on the 
randomization scheme to ensure 
allocation concealment. A single 
pharmacist was involved in the 
packaging of all medications into sterile 
boxes with labeling them as 1, 2 and 3.  
Randomization  
A statistician, not otherwise engaged in 
the study, prepared a computer-
generated random table and placed the 
allocation data in serially numbered 
sealed opaque envelopes. Each 
envelope had a card noting the group 
identifier inside. The key for the allocation 
of identifying serial numbers to members 
of each group was kept until the end of 
the study by the statistician. The 
investigators responsible for IUD 
placement and data collection were 
blinded to group allocations. In addition, 
both the patients and the statistician who 
did the final data analysis were blinded to 
group allocations. Once the allocation 
had been made, it could not be changed. 
Study intervention 
Prior to placement of IUDs, baseline 
data, including a complete evaluation of 
patient history as well as general, 
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abdominal and pelvic examination of all 
study participants was performed by the 
same study investigator. The same 
investigator also instructed the 
participants on the use of the 
standard10-cm VAS for pain scoring. A 
different study investigator, with ten 
years of experience in family planning 
services, inserted the IUD 
(ParaGard®T380A; Cooper surgical, 
USA, Inc. North Wales) for all 
participants using the standard technique 
of application prescribed by the 
manufacturer. IUD insertion was 
performed while women were 
menstruating. The day of the menstrual 
cycle ranged from the first to the fifth. 
To insert the IUD, a speculum was 
placed into the vagina and the cervix was 
cleansed with povidone-iodine. Then, the 
anterior lip of the cervix was grasped with 
a single toothed vulsellum tenaculum for 
fixation of the uterus, and a metal uterine 
sound was inserted for measurement of 
uterine length, followed by IUD insertion. 
This standard Copper IUD placement 
technique was used for all participants 
without the aid of ultrasound guidance. 
Any complications, such as tenaculum 
site bleeding, uterine perforation and 
failure of insertion were recorded when 
and if they occured. 
During the procedure, the patient's pain 
perception was assessed using VAS 
graded from zero to 10 with zero 
corresponding to no pain and 10 
corresponding to the worst possible pain. 
A study investigator was standing beside 
the patient during IUD placement with 
copies of the 10-point VAS printed on 
multiple sheets of paper. The patient was 
asked to mark her level of pain on a copy 
of the VAS at four points during the 
procedure: during tenaculum placement, 
during sound insertion, at time of IUD 
placement and five minutes after the end 
of placement.  
After placement, the investigator who 
inserted the IUD evaluated the ease of 
insertion score (ES) using a graduated 
VAS-like scale from zero to 10; on which 
10 meant a terribly difficult procedure and 
zero meant a very easy procedure.8 
Patients were asked by the investigator if 
they needed additional analgesia at 15 
minutes after IUD placement. Finally, 
patients were asked to report any 
adverse reactions experienced after the 
intake of the study medications through 
an open-ended question about 
medication side effects. 
Statistical analysis 
Data coding and data entry were done 
using the statistical package SPSS 
(Statistical Package for the Social 
Sciences) version 22 (Armonk, NY: IBM 
Corp). Data were summarized as mean 
and standard deviation for quantitative 
data and as frequency and percentage 
for categorical data. The differences 
(MD) between any two groups was 
reported as a mean and its 
corresponding 95% confidence interval. 
Comparisons between quantitative 
variables were made using non-
parametric Kruskal-Wallis and Mann-
Whitney tests. For comparing categorical 
data, Chi-square (X2) tests were 
performed. P-values less than 0.05 were 
considered as statistically significant. 
Results 
At enrollment, 145 women were eligible 
for inclusion in our study; however, a total 
of 105 actually participated. Of those 
eligible for inclusion, 25 chose not to 
participate, while 15 potential 
participants were ineligible as they had 
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been delivered by emergency CS. The 
remaining 105 participants were 
randomly allocated to groups for a total of 
35 per group (Figure 1). 
 
 
Figure1. Flowchart of the study participants. 
 
Study outcomes The primary outcome of the study was 
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the mean value of VAS scores during 
IUD placement across the study groups. 
Secondary outcomes included the mean 
VAS score at various other stages during 
the insertion procedure, the mean of the 
physician-determined score for ease of 
IUD insertion, the duration of the 
placement procedure, the rate of need for 
additional analgesia and the side effects 
of the study medications. 
The baseline characteristics of the study 
participants are illustrated in Table 1 and 
showed that there was no statistically 
significant difference across all three 
groups. A subgroup study, comparing pain 
scores from lactating and non-lactating, 
placebo users found no difference between 
the groups (p=0.413) 
Table 1: The baseline characteristics of the women according to the medication 
used prior to IUD insertion 
 
Characteristics Celecoxib group 
(N= 35) 
HBB group 
(N= 35) 
Placebo group 
(N= 35) 
P-value 
Age 28.37±6.48 29.49±6.93 29.09±7.18 0.825 
Gravidity 3.03±1.81 2.83±1.15 3.11±1.25 0.456 
Parity 2.49±1.27 2.37±1.09 2.66±1.21 0.530 
BMI 31.40±6.91 29.29±5.86 30.66±5.05 0.283 
Education  
0.716 Primary 24(68.6%) 25(71.4%) 27(77.1%) 
High  11 (31.4%) 10 (28.6%) 8 (22.9%) 
Interval from last delivery  
0.766 <6 months 16(45.7%) 17(48.6%) 19(54.3%) 
>6 months 19(54.3%) 18(51.4%) 16 (45.7%) 
Previous IUD insertion  14 (40.0%) 18 (51.4%) 17 (48.6%) 0.608 
Lactational status  
0.631 Lactating 21 (60.0%) 19 (54.3%) 17 (48.6%) 
Not lactating 14 (40.0%) 16 (45.7%) 18 (51.4%) 
HBB; hyoscine butyl bromide, BMI; body mass index, IUD; intrauterine device 
 
In this study, VAS pain scores showed 
significant differences for tenaculum 
placement, sound insertion and IUD 
insertion as well as for ease of insertion 
(p<0.001 for all). However, differences 
were not statistically significant with 
regard to the duration of insertion, the 
need for additional analgesia and 
tenaculum site bleeding across all groups 
(p=0.460, p=0.179 and p=0.183, 
respectively) (Table 2). No member of 
any group needed cervical dilatation for 
IUD insertion. 
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Table 2: The study outcomes during IUD insertion according to the medication 
used prior to the procedure. 
Study Outcomes Celecoxib group 
(N= 35) 
HBB group 
(N= 35) 
Placebo group 
(N= 35) 
P-value 
VAS tenaculum placement, cm 2.24±0.99 2.30±0.95 3.83±1.02 < 0.001 
VAS sound insertion, cm 1.88±1.12 2.23±0.73 4.14±0.73 < 0.001 
VAS IUD insertion, cm 1.97±1.03 2.91± 0.82 4.34±0.87 < 0.001 
VAS 5 minutes post-insertion, cm 1.06±0.89 1.23±0.69 2.86±0.77 < 0.001 
Ease of insertion score, cm 1.56±0.61 1.43±0.78 3.03±1.29 < 0.001 
Duration of insertion, sec 56.79± 8.35 55.83±11.48 54.40±10.74 0.460 
Failure of insertion 0 0 0 ------ 
Perforation 0 0 0 ------ 
Need for additional analgesia 3 (8.8) 4 (11.4) 3 (8.8) 0.179 
Tenaculum site bleeding 3 (8.8) 4 (11.4) 4 (11.4) 0.183 
HBB; hyoscine butyl bromide, VAS; visual analog scale, IUD; intrauterine device 
Data are presented as the absolute mean± standard deviation or n (%) 
 
When compared with women taking 
placebo, women in the celecoxib group 
had significantly lower pain during 
tenaculum placement [mean difference 
(MD)=1.59, 95% confidence interval (CI): 
1.06-2.12, p<0.001], sound placement 
[MD= 2.26, 95% CI: 2.61 - 7.13, p< 
0.001], IUD insertion [MD= 2.37, 95% CI: 
0,39-4.35, p< 0.001] and five minutes 
post-insertion [MD =1.8, 95% CI: 0.3-3.3, 
p< 0.001] with greater ease of insertion 
score [MD= 1.47, 95% CI: 0.7-9.94, p< 
0.001].  
Although differences between study 
groups were not large, they were 
significant. For example, women in the 
celecoxib group were also more likely to 
report lower overall pain scores during 
IUD insertion (1.97 vs 4.34, p<0.001). 
The same was observed with pain scores 
during speculum placement, tenaculum 
placement and sound insertion 
(p<0.001). There was also a decrease in 
pain scores at five minutes after IUD 
insertion (1.06 vs. 2.86, p<0.001) (Table 
2). Although the difference between both 
groups was statistically significant, no 
clinically significant difference was found 
as the MD was less than 2 cm. 
Similarly, women in the HBB group had 
significantly lower tenaculum pain when 
compared with placebo during IUD 
placement [MD=1.53, 95%CI: 0.66-2.4, 
p< 0.001], IUD placement [MD= 1.43, 
95% CI: 0,8-2.65, p< 0.001]; sound 
placement [MD= 1.91, 95% CI: 1.89 – 
1.93, p< 0.001], and five minutes post-
insertion [MD= 1.63, 95% CI: 0.63-2.63, 
p< 0.001] as well as lower (easier) ease 
of insertion scores [MD= 1.60, 95% CI: 
0.4.75 - 7.95), p< 0.001]. Furthermore, 
women in HBB group were more likely to 
report lower overall pain scores during 
IUD insertion (2.91 vs 4.34, p<0.001). 
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Moreover, pain scores during speculum 
placement, tenaculum placement and 
sound insertion were significantly lower 
(p<0.001). There was also a decrease in 
pain scores at five minutes after IUD 
insertion (1.23 vs. 2.86, p<0.001) (Table 
2). However, the difference between 
these groups was not clinically 
significant. 
Women in the celecoxib group had 
tenaculum pain scores that were similar 
to those for patients receiving HBB 
during IUD placement [MD =0.06, 95% 
CI:-0.38-5, p=1.00], IUD placement pain 
[MD= 0.94, 95%CI:-0.13-0.50, p= 0.05], 
sound placement [MD= 0.35, 95%CI:-
4.44-5.14, p=0.641], five minutes post-
insertion [MD= 0.17, 95%CI-2.23-2.57), 
p= 1.000]; ease of insertion score [MD= 
0.13, 95%CI: -2,01-2.27 , p= 1.00]. 
Complications and side effects had little 
impact on outcomes for this study. In all 
groups, none of the procedures resulted 
in perforation. None of the women who 
received celecoxib had nausea, but six 
patient who received HBB and three 
women in the placebo group suffered 
from nausea (p=0.039) after IUD 
insertion. None of the women who 
received placebo had dryness of mouth 
versus one in the celecoxib group, and 
six in the HBB group (p=0.016). None of 
the women who received placebo had 
dizziness versus three in the celecoxib 
group and four in the HBB group 
(p=0.157). 
Discussion 
One of the main barriers for IUD use is 
the fear of pain experienced during 
insertion. Therefore, improved pain 
control during insertion could enhance 
IUD use and decrease the rate of 
unplanned pregnancies.2 To the best of 
our knowledge, this is the first trial to 
study oral celecoxib (a selective COX-2 
inhibitor) and HBB to reduce pain 
associated with copper IUD placement. 
Our VAS results show that HBB (100 mg) 
and oral celecoxib (100 mg) significantly 
decreased the pain during tenaculum 
placement, sound placement, IUD 
placement and five minutes post-
insertion, and increased ease of insertion 
scores, as compared with placebo. No 
significant difference in the mean pain 
scores was observed between HBB and 
celecoxib during any step of IUD 
placement. 
Several RCTs have studied the use of 
various analgesics for reducing pain 
associated with IUD placement. Abbas et 
al. reported that the use of oral diclofenac 
potassium slightly reduced pain during 
tenaculum application and IUD 
placement. However, when comparing 
diclofenac potassium with HBB, Abbas 
found oral diclofenac potassium was 
more effective.21 Also, Fouda et al. 
reported that the use of oral diclofenac 
potassium combined with lidocaine gel 
slightly induced pain reduction during 
tenaculum application and IUD 
placement.5 Bednarek et al. compared 
Ibuprofen 800 mg with placebo during 
IUD placement, but they reported no 
reduction of pain associated with its 
use.12 
On the other hand, one randomized 
controlled trial of 103 women found that 
either 550 mg of naproxen or 50 mg of 
tramadol one hour before IUD placement 
in multiparous women reduced 
procedure pain as compared with 
placebo. Mean pain scores were 2.3 in 
the tramadol group, 2.9 in the naproxen 
group and 4.9 in the control group. 
Tramadol was statistically superior to 
naproxen, and both were statistically 
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superior to the placebo.22 
In a pilot RCT, intramuscular ketorolac 30 
mg given 30 minutes before the 
procedure was found to be superior to 
saline for IUD placement pain (5.8 vs. 
8.2, p< 0.02).10 Another study showed 
that giving oral ketorolac 40-60 minutes 
before IUD placement is effective in 
reducing pain overall pain, pain during 
IUD insertion, and pain 10 minutes post-
procedure.23 However, this same effect 
was not detected in the 51 multiparous 
women who were part of the trial, 
although multiparous women in the 
ketorolac arm had less pain at both 5 and 
15 minutes after the procedure. 
We could find no report on the use of 
celecoxib or any other non-selective 
COX 2 inhibitor during IUD placement. 
Celecoxib has shown greater 
effectiveness than tramadol before 
hysteroscopy in reducing pain evoked by 
the procedure. Furthermore, celecoxib is 
better tolerated with no reported side 
effects.24 
In our own study, side effects, including 
nausea and dryness of the mouth were 
rarely reported among women in the 
celecoxib group as compared to those in 
the HBB group. Celecoxib, as a selective 
COX-2 inhibitor, is less likely to cause the 
side effects of non-selective NSAIDs and 
opioids. Although there has been 
concern over the risk of major 
cardiovascular events (non-fatal 
myocardial infarction and stroke), the risk 
with selective COX-2 inhibitors was 
found to be dose-dependent and similar 
to that of most non-selective NSAIDs.25 
The key strength of our study is the 
randomized design. We were able to 
recruit the calculated sample size for 
achieving adequate power to detect a 
clinically significant difference in VAS 
scores. Additionally, the study was 
conducted at the same clinic, with a 
single, experienced investigator 
performing IUD insertion to avoid any 
inter-assessor variation in VAS score 
evaluation.  
The main limitation of the study is the 
subjectivity in reporting pain through VAS 
scores. However, it is a widely accepted 
method, and there are currently no other 
objective parameters for evaluating pain. 
Another limitation that may affect the 
generalizability of the study is that we 
tested both drugs only during placement 
of a copper IUD. Finally, a substantial 
proportion of our study participants were 
breastfeeding, which is known to mask 
pain during IUD placement. This 
confounding factor may also be a 
limitation to this study.  
In conclusion, the use of celecoxib and 
HBB reduce the pain associated with 
copper IUD placement in women with no 
previous vaginal delivery. We need to 
carry out further RCTs with a larger 
sample size to confirm these findings. 
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